ArticleFrontiers in immunology2025
Adjuvant radiotherapy for patients with clinical T3-4 oral and oropharyngeal cancer who achieved major pathologic response after neoadjuvant immunochemotherapy and surgery: a propensity score-matched retrospective study.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neoadjuvant chemotherapy combined with immunotherapy results in high pathologic response rates in locally advanced oral and oropharyngeal cancer (OC/OPC). It is unclear if patients with clinical T3-4 (cT3-4) OC/OPC at initial diagnosis can safely omit adjuvant radiotherapy (ART) after significant pathological downstaging. Methods: This retrospective cohort study included cT3-4 OC/OPC patients who achieved a major pathologic response (MPR) after neoadjuvant immunochemotherapy between July 2019 and May 2024. Patients were categorized by whether they received ART. Propensity score matching was used to balance baseline characteristics. Local recurrence-free survival (LRFS), locoregional recurrence-free survival (LRRFS), distant metastasis-free survival (DMFS), and overall survival (OS) were compared between cohorts. Results: A total of 247 patients were eligible, with a median follow-up of 31 months (IQR, 20-41). The 2-year survival outcomes were favorable: LRFS 93.4%, LRRFS 85.0%, DMFS 95.6%, and OS 93.0%. In the matched cohorts (74 pairs), ART significantly improved 2-year LRFS (100% vs. 85.5%, Conclusions: Omitting ART in patients with cT3-4 OC/OPC who achieve MPR after neoadjuvant immunochemotherapy and surgery significantly compromises oncological outcomes. Further investigation is necessary to optimize adaptive de-escalation strategies for this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.